TMDX
TransMedics Group, Inc.
Is TMDX Halal?
Organ-preservation and transplant-management technology — generally permissible medical activity, but current debt and receivables screens fail.
What You Should Know
TransMedics' March 31, 2026 Form 10-Q reports assets of $1,434.820 million, debt and finance leases of $857.024 million, cash of $461.739 million, receivables of $90.727 million and quarterly revenue of $173.933 million. Debt/assets is 59.73%, liquidity/assets is 32.18% and receivables plus cash/assets is 38.52%; debt and receivables screens fail. Mixed other income is not used as a gross interest numerator.
⚠️ Concerns
- •Debt/assets is 59.73%, above examined limits
- •Receivables-plus-cash/assets is 38.52%, above the examined MSCI limit
- •Convertible notes and finance-lease leverage
- •Clinical, regulatory and reimbursement exposure
- •No universal prohibited-revenue numerator or gross interest-income amount is disclosed
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-15.
857.024 / 1,434.82
461.739 / 1,434.82
552.466 / 1,434.82
- Financial
- Fails
- Overall
- Fails
Debt/assets is 59.73%, liquidity/assets is 32.18% and receivables-plus-cash/assets is 38.52%; debt and receivables screens fail.
- Financial
- Fails
- Overall
- Fails
Debt/assets and receivables-plus-cash/assets exceed the examined limits; this is not an index-membership claim.
- Financial
- Fails
- Overall
- Fails
Debt/assets is 59.73%, above the examined limit; this is not an official classification.
- Financial
- Not calculated
- Overall
- Fails
A licensed historical market-cap series is not stored; asset-based debt screens already fail.
Business-activity disclosure
TransMedics provides organ-preservation, transport and transplant-management technology and services. Medical technology is generally permissible, but customer and clinical end-use allocation is not reduced to a universal prohibited-revenue numerator.
Limitation: No universal prohibited-activity revenue numerator or scholar-specific purification percentage is disclosed.
Purification
The filing does not provide a separable gross interest-income amount; ZakatInvest does not infer a purification amount.
Inputs, assumptions and primary sources
- Amounts are USD thousands from TransMedics' March 31, 2026 Form 10-Q; this record expresses them in millions-equivalent values.
- Debt includes current debt of $15.000 million, convertible senior notes of $453.530 million, long-term debt of $44.665 million and finance-lease liability of $343.829 million; operating leases are excluded.
- Cash is $461.739 million and accounts receivable is $90.727 million.
- Quarterly revenue is $173.933 million. Mixed interest income and other income (expense), net is not used as a gross interest numerator.
- Organ-transplant technology and clinical services are generally permissible, but no universal prohibited-revenue numerator is disclosed.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →